Lessons from the pandemic: Responding to emerging zoonotic viral diseases—a Keystone Symposia report
暂无分享,去创建一个
J. Epstein | L. Madoff | M. V. Van Kerkhove | A. Fauci | S. Günther | W. Dowling | S. Frost | E. Saphire | C. Muñoz-Fontela | D. Bausch | L. Hensley | F. Krammer | E. de Wit | N. van Doremalen | M. Gunn | M. Krieger | Lin‐Fa Wang | T. Jaenisch | Jennifer Cable | S. Gilbert | T. Geisbert | S. Baize | L. M. Branco | P. Yadav | Kizzmekia S. Corbett | É. Bergeron | D. Hartman | Simon D. W. Frost | P. Nordenfelt | D. Bente | R. Hesselink | I. Sitaras | S. A. C. Clemens | May C. Chu | R. Arora | Pontus Nordenfelt | Luis M. Branco
[1] E. Saphire,et al. Neutralizing Antibodies against Lassa Virus Lineage I , 2022, mBio.
[2] D. Feikin,et al. Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera , 2022, Vaccines.
[3] E. Saphire,et al. Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies , 2022, Cell reports.
[4] G. Guyatt,et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19 , 2022, The New England journal of medicine.
[5] S. Panda,et al. Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against alpha, Beta, Delta and omicron variants of concern. , 2022, Journal of travel medicine.
[6] N. Lurie,et al. Delivering Pandemic Vaccines in 100 Days - What Will It Take? , 2022, The New England journal of medicine.
[7] M. Nilges,et al. Bat coronaviruses related to SARS-CoV-2 and infectious for human cells , 2022, Nature.
[8] Robert J. Fischer,et al. Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model , 2022, Research square.
[9] A. Nardone,et al. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021 , 2022, BMJ Global Health.
[10] N. Foskett,et al. Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination , 2021, The Lancet Global Health.
[11] Lydia M. Roberts,et al. Age-related differences in immune dynamics during SARS-CoV-2 infection in rhesus macaques , 2021, Life Science Alliance.
[12] OUP accepted manuscript , 2022, Journal of Travel Medicine.
[13] Hamed Khakzad,et al. Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2 , 2022, Frontiers in Immunology.
[14] W. Lipkin,et al. Natural history of nonhuman primates after conjunctival exposure to Ebola virus , 2021, bioRxiv.
[15] A. Nardone,et al. Global epidemiology of SARS-CoV-2 infection: a systematic review and meta-analysis of standardized population-based seroprevalence studies, Jan 2020-Oct 2021 , 2021, medRxiv.
[16] J. Lopez Bernal,et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply. , 2021, The New England journal of medicine.
[17] A. Nardone,et al. Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID‐19 pandemic , 2021, Influenza and other respiratory viruses.
[18] Hyeong Mi Kim,et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study , 2021, Science.
[19] Jitendra Narayan,et al. Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India , 2021, Viruses.
[20] G. Guyatt,et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial , 2021, The Lancet Global Health.
[21] M. Chen,et al. Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors , 2021, The New England journal of medicine.
[22] H. Mullerova,et al. Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis , 2021, The Lancet.
[23] R. Myers,et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.
[24] R. Horstmeyer,et al. Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR , 2021, Science Translational Medicine.
[25] G. Screaton,et al. Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine , 2021, ACS central science.
[26] Robert J. Fischer,et al. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge , 2021, NPJ vaccines.
[27] J. Woodcock,et al. Trends in COVID-19 therapeutic clinical trials , 2021, Nature Reviews Drug Discovery.
[28] Nguyen H. Tran,et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials , 2021, The Lancet.
[29] Timothy D. Flietstra,et al. High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay , 2020, Scientific Reports.
[30] A. Casadevall,et al. Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. , 2020, The New England journal of medicine.
[31] R. Hai,et al. H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model , 2020, mBio.
[32] J. Epstein,et al. Nipah virus dynamics in bats and implications for spillover to humans , 2020, Proceedings of the National Academy of Sciences.
[33] D. Skovronsky,et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 , 2020, The New England journal of medicine.
[34] Lisa E. Gralinski,et al. Animal models for COVID-19 , 2020, Nature.
[35] J. Epstein,et al. Possibility for reverse zoonotic transmission of SARS-CoV-2 to free-ranging wildlife: A case study of bats , 2020, PLoS pathogens.
[36] A. Fauci,et al. Emerging Pandemic Diseases: How We Got to COVID-19 , 2020, Cell.
[37] Rebecca J. Loomis,et al. SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.
[38] V. Munster,et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.
[39] M. Chen,et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction , 2020, Nature Biotechnology.
[40] M. Nussenzweig,et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies , 2020, Cell.
[41] G. Alter,et al. Dissecting antibody-mediated protection against SARS-CoV-2 , 2020, Nature Reviews Immunology.
[42] S. Anzick,et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 , 2020, Nature.
[43] Joshua C. Johnson,et al. Natural History of Aerosol Induced Lassa Fever in Non-Human Primates , 2020, Viruses.
[44] M. Nussenzweig,et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.
[45] Anna María Nápoles,et al. COVID-19 and Racial/Ethnic Disparities. , 2020, JAMA.
[46] E. Fischer,et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2 , 2020, Nature.
[47] B. Graham,et al. Prototype pathogen approach for pandemic preparedness: world on fire. , 2020, The Journal of clinical investigation.
[48] S. Anzick,et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 , 2020, Nature.
[49] F. I. Ibukun,et al. Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development , 2020, Viruses.
[50] Catharine I Paules,et al. Coronavirus Infections-More Than Just the Common Cold. , 2020, JAMA.
[51] Eurosurveillance Editorial Team. Note from the editors: novel coronavirus (2019-nCoV) , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[52] C. Muñoz-Fontela,et al. Comparative pathogenesis of Ebola virus and Reston virus infection in humanized mice , 2019, JCI insight.
[53] H. Feldmann,et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death , 2019, The Journal of clinical investigation.
[54] J. Armengaud,et al. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot , 2019, Science Translational Medicine.
[55] James E. Robinson,et al. Antibody therapy for Lassa fever. , 2019, Current opinion in virology.
[56] E. Saphire,et al. Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization , 2019, Cell.
[57] H. Feldmann,et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge , 2019, Science Translational Medicine.
[58] P. Daszak,et al. Transmission of Nipah Virus — 14 Years of Investigations in Bangladesh , 2019, The New England journal of medicine.
[59] P. Daszak,et al. Using healthcare-seeking behaviour to estimate the number of Nipah outbreaks missed by hospital-based surveillance in Bangladesh. , 2019, International journal of epidemiology.
[60] S. Günther,et al. T-Cell Receptor Diversity and the Control of T-Cell Homeostasis Mark Ebola Virus Disease Survival in Humans. , 2018, The Journal of infectious diseases.
[61] Tchoyoson C. C. Lim,et al. Nipah Virus Infection , 2018, Journal of Clinical Microbiology.
[62] C. Picard,et al. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins , 2018, Journal of Virology.
[63] Catharine I Paules,et al. The Critical Role of Biomedical Research in Pandemic Preparedness. , 2017, JAMA.
[64] Donald S. Grant,et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever , 2017, Nature Medicine.
[65] J. Epstein,et al. Convergence of Humans, Bats, Trees, and Culture in Nipah Virus Transmission, Bangladesh , 2017, Emerging infectious diseases.
[66] Barney S. Graham,et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.
[67] L. Madoff,et al. ProMED-mail: 22 years of digital surveillance of emerging infectious diseases. , 2017, International health.
[68] G. Quérat,et al. Implementation of a non‐human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and analysis of virus populations , 2017, Antiviral research.
[69] S. Günther,et al. Ebola virus infection kinetics in chimeric mice reveal a key role of T cells as barriers for virus dissemination , 2017, Scientific Reports.
[70] James O. Lloyd-Smith,et al. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting , 2016, Science.
[71] Lauren A. Cowley,et al. Unique human immune signature of Ebola virus disease in Guinea , 2016, Nature.
[72] Barney S. Graham,et al. Pre-fusion structure of a human coronavirus spike protein , 2016, Nature.
[73] V. Nene,et al. Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever , 2016, Scientific Reports.
[74] Ulas Bagci,et al. Evaluation of candidate vaccine approaches for MERS-CoV , 2015, Nature Communications.
[75] Jay B. Varkey,et al. Human Ebola virus infection results in substantial immune activation , 2015, Proceedings of the National Academy of Sciences.
[76] H. Feldmann,et al. Foodborne Transmission of Nipah Virus in Syrian Hamsters , 2014, PLoS pathogens.
[77] U. Baxa,et al. Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.
[78] H. Feldmann,et al. Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route , 2012, Scientific Reports.
[79] H. Feldmann,et al. Nipah Virus Transmission in a Hamster Model , 2011, PLoS neglected tropical diseases.
[80] L. Madoff. ProMED-mail: an early warning system for emerging diseases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[81] Paul Milligan,et al. Bulletin of the World Health Organization , 2017 .
[82] J. Lederberg,et al. COMMITTEE ON EMERGING MICROBIAL THREATS TO HEALTH , 1992 .
[83] E. Stephenson,et al. Effect of environmental factors on aerosol‐induced lassa virus infection , 1984, Journal of medical virology.
[84] Ebola haemorrhagic fever in Zaire, 1976. , 1978, Bulletin of the World Health Organization.